65.64 -0.08 (-0.12%)
Pre-Market: 8:49AM EDT
|Bid||65.25 x 800|
|Ask||65.70 x 1000|
|Day's Range||65.11 - 66.15|
|52 Week Range||60.32 - 79.61|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||14.24|
|Earnings Date||Oct 23, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||2.52 (3.83%)|
|1y Target Est||80.49|
While the vast majority of our Ultimate Stock-Pickers are not dividend investors, a handful of them--Amana Trust Income AMANX , Columbia Dividend Income LBSAX , Oakmark Equity & Income OAKBX , and Parnassus Equity Income PRBLX --focus more heavily on income-producing stocks in their pursuit of investment return. Warren Buffett at Berkshire Hathaway BRK.B has spoken highly of companies that return capital to shareholders and is not against investing in and holding higher-yielding names, with three of Berkshire's top five holdings--wide-moat rated Wells Fargo WFC , Bank of America BAC , and Coca-Cola KO --accounting for about one third of the insurer's equity portfolio and yielding more than the S&P 500. As you may recall from previous articles, when we screen for top dividend-paying stocks among the holdings of our Ultimate Stock-Pickers, we try to find the highest-quality names that are currently held with conviction by our top managers.
Most of the time analysts issue bullish calls on stocks. So when an analyst publishes a Hold rating, or even more rarely a Sell rating, it’s time to take note. Here are three stocks with a very bearish outlook from Goldman Sachs right now. According to the firm, these 3 stocks all deserve the most worrying ‘underperform’ rating based on their outlook for the coming months. Here we take a closer look at why Goldman Sachs is advising against these three stocks, and whether or not the rest of the Street agrees. Let’s dive in now: Seagate Technology PLCWith the HDD (hard disk drives) market in secular decline, it’s not surprising that Goldman Sachs analyst Mark Delaney remains unconvinced about Seagate Tech (STX– Get Report). His Sell rating comes with a $37 price target- suggesting prices could plummet 34% in the coming months. Indeed, the data storage company has already rallied 46% year-to-date- and for Delaney that’s a key reason for caution going forward. "We believe HDDs remain a cyclical industry, and one facing secular challenges in many parts of the market from the growth of SSDs (solid-state drives) that are based on NAND flash," Delaney told investors when he first downgraded the stock. He also prefers larger storage rival Western Digital (WDC)- which has a more neutral Hold rating from the Goldman analyst. Unlike STX, WDC also has large exposure to NAND flash, thanks to its 2016 SanDisk acquisition.Meanwhile Barclays analyst Tim Long also recently initiated STX with a Sell rating- and an even more bearish price target of $32. He warns that top-line pressure and a possible increase in research and development "could disrupt the capital return to shareholders." Overall STX scores a Hold rating from the Street based on all the ratings published over the last three months. The average analyst price target stands at $47 (16% downside potential). Gilead Sciences IncDrugs giant Gilead (GILD– Get Report) received the thumbs down from Goldman Sachs earlier this year. “We are downgrading GILD to Sell from Neutral and lowering our price target to $60 from $70 which represents -10% downside vs 17% avg upside for the rest of our coverage,” Terence Flynn wrote. Indeed, with Gilead now trading at $66 the analyst’s new $60 price target is one of the Street’s lowest price targets and suggests considerable downside risk lies ahead. With the loss of the blockbuster HCV franchise and near total market dominance in HIV (80% of US patients on anti-retrovirals are on a Gilead product), Gilead is in a period of change as management searches for new avenues to generate growth. "GILD currently trades at ~10x NTM P/E and barring another "Pharmasset" and/or internal pipeline success we find it difficult to see the stock's multiple expanding" says Flynn.According to the analyst, GILD has a “very limited” mid-to-late stage pipeline of drugs under development. The analyst told investors: “[T]he company has a new CEO and we assume that rebuilding the pipeline and improving R&D productivity across the organization will be a key area of focus… This can clearly take time and we anticipate there will be tremendous competition for innovative/growth assets.”However, the rest of the Street is notably more optimistic. Not only are we looking at a Strong Buy analyst consensus, but significant upside potential of 28% according to the average analyst price target. “We look towards the expansion of the pipeline via M&A (i.e., Galapagos so far) to drive long-term growth” writes Maxim analyst Jason McCarthy. He has a buy rating on GILD with an $84 price target. PVH CorpOne of the world’s largest apparel companies, PVH (PVH– Get Report) owns both Tommy Hilfiger and Calvin Klein. However that isn’t enough to win over Goldman Sachs analyst Alexandra Walvis. On August 30 she slashed her price target from $82 to $73 while maintaining a Sell rating. From current levels her price target indicates downside potential of almost 20%.In fact the analyst has recently issued Sell ratings on a number of apparel companies, including Ralph Lauren (RL); Levi Strauss (LEVI) and Tapestry Inc (TPR). So what's driving all these bearish calls?“The combination of persistently tough first-half retail trends and an optimistic spring ordering season has driven inventory overhangs at several multibrand retailers," Walvis revealed. "These retailers are thus tightening up ordering as we head into the critical back-to-school and holiday season. We thus see incremental sell-in risk for apparel brands, particularly those with high exposure to department stores."In particular, the Goldman analyst warned of potentially fading growth at PVH's Tommy Hilfiger brand thanks to its dependence on outlet stores, as well as challenges over at Calvin Klein. “While brands that have been investing in building strong direct-to-consumer omnichannel commerce are likely to be more insulated, we take a more cautious view on nonathletic apparel brands whose direct-to-consumer businesses are skewed towards outlet stores, particularly given challenged traffic trends in these locations,” she said. And a note of caution: Apple Inc Although Goldman Sachs has a Hold rating on Apple (AAPL– Get Report) (rather than Sell) it is worth nothing that analyst Rod Hall just made a notably bearish move on the stock. On September 13 he significantly cut his AAPL price target from $187 to $165 (24% downside potential). He blamed Apple’s accounting practices for the move: “We believe that Apple plans to account for its 1-year trial for TV+ as a ~$60 discount to a combined hardware and services bundle,” wrote Hall.“Effectively, Apple’s method of accounting moves revenue from hardware to Services even though customers do not perceive themselves to be paying for TV+. Though this might appear convenient for Apple’s services revenue line it is equally inconvenient for both apparent hardware ASPs and margins in high sales quarters like the upcoming FQ1′20 to December,” the analyst added.Discover Wall Street’s most loved stocks with the Top Analysts’ Stocks tool
Researchers reported that Atara Biotherapeutics treatment showed hints of actually improving the condition of MS patients, instead of just slowing the disease like most available treatments.
SAN DIEGO, CA / ACCESSWIRE / September 11, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit is pending on behalf of certain consumers related to various drugs from Gilead Sciences, Inc used to treat HIV. Investors, who purchased shares of Gilead Sciences, Inc. (GILD), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554. The plaintiffs allege that Gilead Sciences, Inc. (GILD) and its alleged coconspirators engaged in a long-running scheme to restrain competition with respect to some of the most important drugs used to treat HIV infection.
The South San Francisco startup, initially focusing on sickle cell disease and cystic fibrosis, scored cash from two prominent venture capital outfits and has assembled a management team with connections to Gilead Sciences.
— formal suspension — this week of Britain’s parliament and with anxiety intensifying daily about the imperilled state of liberal democracy on both sides of the Atlantic, the publication of The Testaments could hardly be better timed. Margaret Atwood’s keenly awaited sequel to The Handmaid’s Tale has been heralded by the Bookseller as “the single most exciting publishing event of the year” and is already on the shortlist for the Booker Prize. For anyone still missing the point that this is a political event as much as a literary one, high profile talks to promote The Testaments have been scheduled across the UK for the week leading up to October 31, the current deadline for Britain’s exit from the EU.
Gilead Sciences, Inc. (GILD) and the Elton John AIDS Foundation today announced the launch of the ground-breaking RADIAN initiative at the Fast-Track Cities 2019 conference in London. RADIAN seeks to meaningfully address new HIV infections and deaths from AIDS-related illnesses in Eastern Europe and Central Asia (EECA). RADIAN builds on the existing collaboration between the Foundation and Gilead in the EECA Key Populations (EECAKP) fund, leveraging both organizations’ greater understanding of the region’s needs to drive forward bold and meaningful action to address specific challenges.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Gilead...
Gilead is one of the biggest biotech companies. But recent news and earnings have been mixed. So, is Gilead stock a buy right now? Read on for a full analysis.
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc. The agency said that while the treatments are safe and effective, it had received reports of rare but serious instances of worsening liver function or failure when they were taken by patients with advanced liver disease. Hepatitis C, a liver disease caused by a blood-borne virus, can be cured with antiviral medicines.
The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc. The agency said that while the treatments are safe and effective, it had received reports of rare but serious instances of worsening liver function or failure when these drugs were taken by patients with advanced liver disease.
Glassdoor is out with its rankings of the highest paying jobs and companies in the United States. Yahoo Finance's Zack Guzman, Sibile Marcellus, and Reggie Wade are joined by Courtney Dominguez, Payne Capital Management Financial Advisor, to discuss.